AUA Annual Meeting

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Prospective clinical trial results of lutetium-PSMA suggest the therapy is safe for patients with locally advanced high-risk prostate cancer.

A phase 3 study is underway to evaluate the potential superiority of TAR-200 in combination with cetrelimab to chemoradiotherapy for the treatment of muscle invasive bladder cancer.

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

In the phase 3 HERO trial of relugolix versus standard of care leuprolide in men with advanced prostate cancer, relugolix failed to significantly delay onset of castration resistance.

Patients with BCG-unresponsive, non-muscle invasive bladder cance carcinoma in situ had promising responses to Bacille Calmette-Guérinplus N-803, updated data from cohort A of the phase 2/3 QUILT-3.032 study.

According to secondary analysis results of a phase 3 study, antibody titers and fold changes are possibly predictive of nadofaragene firadenovec efficacy in patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

Real-world evidence shows robust adherence rates and prostate-specific antigen response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

"Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options."

Eric A. Klein, MD, discusses the role of genomic testing in patients with prostate cancer and how these findings can impact treatment decisions.

In an interview with Targeted Oncology, Neal Shore, MD, director, Carolina Urologic Research Center, discussed the OS analysis for the phase 3 ARAMIS study and explained a match-adjusted indirect comparison. He also discussed how these data connect with presentations around the 3 approved agents for nmCRPC being presented at AUA 2020.

“This study is 1 of the first [to report on a] chemoimmunotherapy combination in the second- and third-line setting of metastatic urothelial carcinoma."

Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.

Cabazitaxel demonstrated better patients-reported outcomes compared with either abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer.

"These interim data demonstrate that primary chemoablation of low-grade intermediate-risk non–muscle invasive bladder cancer using UGN-102 results in a significant treatment response and encouraging durability."

Positive safety and efficacy outcomes were witnessed in the KEYNOTE-365 study , supporting further assessment of the combination of pembrolizumab and enzalutamide in a larger population of patients with metastatic castration resistance prostate cancer.

"Historically, neoadjuvant hormone therapy has been shown to improve pathologic outcomes. Therefore, neoadjuvant androgen deprivation therapy may allow a nerve-sparing surgical approach to increase post-surgical quality-of-life outcomes without compromising oncologic outcomes.”

Felix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.

"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."

The efficacy of radium-223 was not impacted by prior treatment with an androgen receptor inhibitor for men with bone metastatic castration-resistant prostate cancer.

Christopher Filson, MD, urology, UCLA Medical Center, discusses a study that used a MR-US fusion biopsy in 1000 men as a method to diagnose high-grade prostate cancer.

Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses screening for prostate cancer.

Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.

Enzalutamide significantly improved progression-free survival and PSA progression compared with bicalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer.